DETAILED NOTES ON (+)-JQ-1 IN EPIGENETICS

For drug discovery geared toward establishing 2nd- or third-generation therapeutics, 1 could reasonably argue that TID/MoA needs to be acquired early in the process to add benefit, as present therapies can be obtained to People in need to have (Figure one). For Many others, especially the neurological and psychiatric illnesses for which TID/MoA is